Novartis AG ADR (NVS)vsDentsply Sirona Inc (XRAY)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
XRAY
Dentsply Sirona Inc
$11.48
-2.55%
HEALTHCARE · Cap: $2.30B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1437% more annual revenue ($56.58B vs $3.68B). NVS leads profitability with a 23.9% profit margin vs -16.3%. XRAY appears more attractively valued with a PEG of 0.82. XRAY earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
XRAY
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+77.0%
Fair Value
$59.47
Current Price
$11.48
$47.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Operating margin of 1.8%
ROE of -36.4% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : XRAY
The strongest argument for XRAY centers on PEG Ratio, Price/Book. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : XRAY
The primary concerns for XRAY are Operating Margin, Return on Equity, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while XRAY is a turnaround play — different risk/reward profiles.
XRAY carries more volatility with a beta of 1.00 — expect wider price swings.
XRAY is growing revenue faster at 6.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
XRAY scores higher overall (56/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Dentsply Sirona Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Dentsply Sirona is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?